As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.

The firm is advancing its AI-driven multi-modal digital pathology platform as a tool for guiding clinical trial design and patient identification.

The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.